Iovance Biotherapeutics (IOVA) to Release Quarterly Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA) is projected to announce its Q1 2025 earnings results after the market closes on Thursday, May 8th. Analysts expect the company to post earnings of ($0.25) per share and revenue of $83.40 million for the quarter. Iovance Biotherapeutics has set its FY 2025 guidance at EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). The company had revenue of $73.69 million during the quarter, compared to analysts’ expectations of $72.17 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Iovance Biotherapeutics Trading Down 11.3 %

Iovance Biotherapeutics stock opened at $3.11 on Wednesday. The firm has a market cap of $1.04 billion, a P/E ratio of -2.08 and a beta of 1.06. Iovance Biotherapeutics has a 1-year low of $2.70 and a 1-year high of $14.13. The firm has a 50-day moving average of $3.45 and a 200-day moving average of $6.25.

Wall Street Analysts Forecast Growth

IOVA has been the subject of a number of recent analyst reports. Robert W. Baird decreased their price objective on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, February 28th. HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Friday, February 28th. Truist Financial dropped their price objective on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Barclays reduced their price objective on Iovance Biotherapeutics from $22.00 to $5.00 and set an “overweight” rating for the company in a report on Monday, April 14th. Finally, Piper Sandler lowered their target price on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating on the stock in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $18.22.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.